VST BIO Corporation has successfully closed its Series A financing round, raising $45 million to advance its stroke therapeutic program, VB-001, into first-in-human studies. The funding, led by Coefficient Giving, will also support the expansion of VST BIO's platform and development capabilities.
Related articles
Press ReleaseSeptember 16, 2026
ASSA ABLOY
ASSA ABLOY acquires PACLOCK in the US
September 16, 2026
Press ReleaseSeptember 16, 2026
MySize
MySize Announces $2.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules
September 16, 2026
Press ReleaseSeptember 16, 2026
Xpansiv
Xpansiv to Acquire Formbay, Australia's AI-Enabled Renewable Energy Certificate and Compliance Technology Platform
September 16, 2026
← Back to all articles
Generated by Olivia 6